Drugs for HAE, MASH Are Among Those Expected to Shake Up Specialty Space

  • Jan 09, 2025

    Various specialty drug-treated conditions are expected to gain new competitors this year, including hereditary angioedema and metabolic dysfunction-associated steatohepatitis. New formulations and expanded indications of already approved agents are also set to impact a variety of diseases, bringing valuable treatments to patients and stressing payers’ financial situation even further. Industry experts spoke with AIS Health, a division of MMIT, about what drugs and/or therapeutic categories should be on payers’ radar in 2025.

    Read more
    © 2024 MMIT
  • Angela Maas

    Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

The Latest
Meet Our Reporters

Meet Our Reporters

×